|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||86.52 - 87.18|
|52 Week Range||73.54 - 95.00|
|Beta (3Y Monthly)||0.54|
|PE Ratio (TTM)||17.79|
|Forward Dividend & Yield||2.83 (3.30%)|
|1y Target Est||101.00|
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
NEW YORK, Oct. 09, 2019 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG.
Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.
The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study
The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
NEW YORK, Sept. 30, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novartis AG (NYSE: NVS) from December 3, 2018 to August.
Roche (RHHBY) gets FDA approval for Rituxan to treat children with two rare blood vessel disorders. The company also extends the offer period to acquire Spark Therapeutics.
Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Novartis was the subject of an FDA statement issued on August 6, 2019. According to the FDA, the Company had submitted manipulated data for its biologics license application (“BLA”) for its gene therapy drug, Zolgensma.
Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex
Novartis AG blamed former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million gene therapy Zolgensma, saying they either personally manipulated the data or pressured subordinates into doing so. The Kaspar brothers were executives at AveXis, the company that developed the drug and was acquired by Novartis for $8.7 billion last year. Last month, the U.S. Food and Drug Administration said Novartis could face civil or criminal penalties because of the data manipulation and the possibility the company had waited to notify regulators.
Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.
NEW YORK, Sept. 23, 2019 -- Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS) concerning.